HTG2014-Section-Header-publications

Categories

Filter by Topics

AACR2023 ALK aplastic anemia AA Autoimmune Disorder B-cell lymphoma Biology of neoplasia Biomarkers Bladder Cancer bone Brain Breast Cancer CD3 Cells Cerebrospinal Fluid clinical trial cold tumor Colorectal cancer Comparison study CXCL12 Cytokines Developmental Immunotherapy Developmental Therapeutics Differential Expression Differential Gene Expression Analysis DLBCL Drug Response Drug sensitivity EHE cancer Encephalophy EPCORE NHL-1 ERBB3 FFPE Gene Expression Profiling Genetic Polymorphism Heart Histone Deacetylase Inhibitors hot tumor HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System HTP Immune Checkpoint Inhibitors Immune Response Immune-related Colitis Immuno-Oncology IMMUNOSARC Immunotherapy IOA- 244 IRP Kidney Liposarcoma liver Liver Lung lungs Lymphoma lymphoma melanoma Melanoma Microenvironment miRNA miRNA WTA Molecular Characterization Nash and Fibrosis Natural Killer Cells Nestin+ Neurologic non-Hodgkin Lymphoma Non-Hodgkin lymphoma NHL OBP Oesophageal Adenocarcinoma Oral cancer oral squamous cell carcinoma OSCC PanB Pancreas pancreatic ductal adenocarcinoma PDAC Parkinson's Disease Pathway Analysis PDX model PI3K inhibitors PIP Plasma Platform Comparison Programmed cell death protein 1 Prostate qNPA qPCR Radioimmunotherapy Rheumatoid Arthritis Sarcoma Serum Signatures soft tissue sarcoma Sub-typing Survival plots T cells Thymic Carcinoma Tislelizumab TME Transplantation Treatment Outcome Treatment Targets Tumor Biology Tumor Immunobiology Tumor infiltrating lymphocytes Zanubrutinlb

2022

SABCS 2022: HER2-06: Outcome analysis of HER2-zero or HER2-low hormone receptor-positive (HR+) breast cancer patients - characterization of the molecular phenotype in combination with molecular subtyping

Download pdf 1.0MB
View External Link

SABCS 2022: PD4-02: Spatial and temporal heterogeneity of predictive and prognostic signatures in triple-negative breast cancer treated with neoadjuvant combination immune-chemotherapy

Download pdf 942KB
View External Link

SABCS 2022: PD-17-05: Development and Validation of a Composite Biomarker Predictive of Palbociclib + Endocrine Treatment Benefit in Early Breast Cancer: PENELOPE-B and PALLAS Trials.

Download pdf 964KB
View External Link

Prognostic Value of EZH2 Expression for Immunotherapy-based Schemes in Advanced Soft-tissue Sarcoma

Download pdf 2.1MB

Biomarkers for Response to Immunotherapy in Triple-Negative Breast Cancer - Differences Between Survival and pCR Biomarkers

Download pdf 674KB

2021

Biological processes associated with the efficacy of sunitinib plus nivolumab in soft tissue sarcoma: correlative studies of the IMMUNOSARC trial of Spanish (GEIS) and Italian (ISG) sarcoma groups - poster

Lacerenza, S., et al., Biological processes associated with the efficacy of sunitinib plus nivolumab in soft tissue sarcoma: correlative studies of the IMMUNOSARC trial of Spanish (GEIS) and Italian (ISG) sarcoma groups

Download pdf 1.0MB

Safety and efficacy of CD3-Targeting Naratuximab Emtansine plus Rituximab in Diffuse Large B-cell Lymphoma and Other Non-Hodgkin's B-cell Lymphomas - a Phase 2 Study

Levy, M. Y., et al. Safety and efficacy of CD3-Targeting Naratuximab Emtansine plus Rituximab in Diffuse Large B-cell Lymphoma and Other Non-Hodgkin's B-cell Lymphomas - a Phase 2 Study. Poster presentation presented at: 16th International Conference on Malignant Lymphoma (ICML) Lugano. June 18-22, 2021

View External Link

Molecular High Grade (MHG) gene expression profile in DLBCL is enriched among patients with early treatment failure

Molecular High Grade (MHG) gene expression profile in DLBCL is enriched among patients with early treatment failure. Poster presentation presented at: 16th International Conference on Malignant Lymphoma (ICML) Lugano. June 18-22, 2021

Download pdf 3.4MB

Page last updated May 22, 2023